૤ଅຫࠬછ࢓߲ુ‫ܔ‬૞຃Ȃಎന࠻ং൐ཆఱ‫֓ڠ‬ၷΓϋΗȜఱ‫ޘ‬ພ֭ ଅ௫ඤ‫ش‬ńŢųťŪŰ ųŦůŢŭ ŢůŦŮŪŢ ŴźůťųŰŮŦŏŰţŶũŪŬŰ ŋŰŬŪĭ ŌŦůūŪ ŏŢŬŢŵŢŕŰũŰ ŖůŪŷŦųŴŪŵź ŐũŢŴũŪ ŮŦťŪŤŢŭ ńŦůŵŦųĭ ŅŪŷŪŴŪŰů Űŧ ŏŦűũŰųŭŰťźɃ͉̲͛ͅɄຫ͉ࠬ୤ࠬ‫ݩ‬ତ͞ΰζΠ·ςΛΠ͉̩́̈́ΰκΈυΫϋȪŉţȫ͈೩౵ͬ̽̀͜૷౯̳ͥȃ̭͉ͦ୤ࠬ‫̹ͥ৽͈ݩ‬൱̧̦஠૸௫‫ॸ͈͒ܕ‬ள‫׋‬เ̜́ͤȂ̷͈‫׋‬เͬ౜̠͈̦ŉţ̺̥̜ͣ́ͥȃຫࠬᑋۛ‫̦ۼܢ‬ౣ‫̷͕̜̓ͦ͊ͦ́ۼܢ‬ఱ̧̈́࿚ఴ͉̞̦̈́Ȃତ̥࠮ոષ঵௽̳ͥાࣣ͉ຫ֦̳ࣣࠬܳͥͅ໵છ̧̹̳ͬ‫خ‬ෝ଻̦̜ͥȃ̷͈యນ̦૤௫৖̜ۛ́ͥȃਔ౶͈̮̩͂ྕ଻ଅ௫ພ͉́૤৖ۛͬࣞອഽࣣͅ໵̳ͥȃ̭͈૤৖̦̳͓ۛ̀ຫ̥̹̯͉ࠬͣͣͦͥ͂͜࡞̞ඳ̞̦Ȃ‫۾͈̥ͣة‬Ⴒ̦̜ͥ͂ࣉ̢༷̦ͥুட̜́ͥȃଅ଻ຫ͈ࠬພఠ୆ၑ̞ٜ̾̀ͅ୰̱͙̹̞̀ȃຫ͈ࠬ૤௫͈͒‫ޣג‬Ȫ&DUGLRUHQDO DQHPLDછ࢓߲ȫŉţ೩‫ͤ͢ͅئ‬ழ૕͈͒ॸள‫ྎ͂ͥࡘ̦ݯރ‬ઑࠬ‫ڐͬۯ‬ಫ̱ழ૕‫ۺ‬ၠͬ௩̳యੲ̦୆̲Ȃ̭͈ྎઑࠬ‫ڐۯ‬ಫ̦ˎষഎͅ࢐ۜ૰ࠐࠏ͞τΣϋͺϋΐ΂ΞϋΏϋȆͺσΡΑΞυϋࠏ͈ᄤૺ̦̾̈́ͥͅȃ̭͈ͦͣ૰ࠐ‫֦଻ס‬ঊ͈‫͉ا଻ڰ‬ଅࠬၠͬ೩‫͂ئ‬ଅ௫͈́କȆŏŢ͈ठ‫ݟ‬ਓ௩‫̦ͤ̈́̾ͅح‬Ȃఘ‫ס‬ၾ௩‫̥ࣞͣح‬૤ฏ੄ၾેఠ̦͒͂̾̈́ͥȃ̭͈ે‫͈ޙ‬஗‫͉װ‬૤௫ςκΟςϋΈͬည൵̱૤๬ఱ̦ૺ࣐Ȃ̞͉̠͌̀̽ࠬ଻૤ະ஠͈ව̦֭͒͂̾̈́ͥˍĪȃ̹͘ຫࠬͤ͢ͅ૤޼ळ༾͈͒ॸள‫̦ݯރ‬၂̻༷֚ͥ́Ȃࣞ૤ฏ੄ેఠ͉́૤ॽমၾ̦௩‫̤̱ͤ̀ح‬Ȃ૤޼ळ༾̤̫ͥͅॸள਑ါ͂‫͈ݯރ‬ΨρϋΑ̦༲̳̩ͦ̈́ͤ͞‫ࠬݹ‬ఛ଻͈೩̞ள౷͂̈́ͥȃྕ଻ଅ௫ພ͈ࠐًಎ͈ഐ୨̈́ŉţ౵͈‫ۯ‬ၑ̦ਹါ̜̭̦́ͥ͂ࡉ̢̩̀ͥȃ૤ଅຫࠬછ࢓߲̞̠͂‫ٽ‬ැ͉ȂŔŪŭţŦųţŦųŨ̦ͣ૤ະ஠ࣣͬ໵̱̹ྕ଻ଅ௫ພۛ৪ͬచયͅȂ୤ࠬ‫ݩ‬௮ࠬঁ֦ࠣঊୋस ĩņųźŵũųŰűŰŪŦŴŪŴ ŔŵŪŮŶŭŢŵŪůŨ łŨŦůŵĻ ņŔłĪ ͂୓ಕഘसͬဥ̞̀ຫࠬহၷ࣐̹̭ͬ̽͂ͧȂຫࠬ͂͂͜ͅ૤‫ܥ‬ෝ͞ଅ‫ܥ‬ෝͬ٨஝̱̹̳͂ͥ༭͉̲࣬ͥ͘ͅˎĪȃ൳ࡄ‫઀͉ݪ‬ତ႕ͥ͢ͅ࠿൦͉̜͈͈́ͥ͜Ȃຫࠬহၷͤ͢ͅঝ‫ݩ‬ఘᚹًၾ ĩňŭŰŮŦųŶŭŢų ŇŪŭŵųŢŵŪŰů œŢŵŦĻ ňŇœĪ͉̲ͬ͛Ȃ૤ະ஠͈ਹછഽ໦႒̜́ͥŏŚŉł ·ρΑ ĩŏŦŸ ŚŰųŬ ŉŦŢųŵ łŴŴŰŤŪŢŵŪŰů ŧŶůŤŵŪŰůŢŭŤŭŢŴŴŪŧŪŤŢŵŪŰůĪȂऒ৒ߐ੄ၚ͉٨஝̳̭ͥ͂ͬྶ̥̱̞ͣ̀ͥͅȃ̱̹̦̽̀Ȃଅ௫ພۛ৪̤̫ͥͅഐ୨̈́ຫࠬহၷ͉૤༗ࢌ͈۷ത̥ͣ͜ఱ̧̈́փྙͬ঵̾ȃഘࠧཋ͈͒෻ၪഘࠧཋࣣͬ໵̳ͥ૤ະ஠ۛ৪ͅచ̳ͥഘ༞ਰၷ༹͂Ȃু‫ژ‬છે͞૸ఘ‫ܥ‬ෝ͈٨஝Ȃව͈֭ςΑ·͈ࠚࡘ͈͂‫۾‬Ⴒ̦ঐഊ̯̞ͦ̀ͥˏƥːĪȃ‫ྙޟ‬૬̞͈͉Ȃ̭͈‫۾‬Ⴒ͉ŉţ౵͉͂ඊၛ̱̀෇̭̜͛ͣͦͥ͂́ͥȃ૤޼ඤ͈ηΠ΋ϋΡςͺ͈΀ΥσΆȜॲ୆͉ͅॸ‫ࡓۺا‬฽؊̦ਹါ̜̦́ͥȂً̭͈೾ͬ૘෾̳ͥࣖள͈‫଻ڰ‬ಎ૤̱͂̀൱̩ഘ͉ȂηΠ΋ϋΡςͺ̤̫ͥͅ΀ΥσΆȜ୆଼͉ͅຈଌ̜́ͥ͂࡞̞ͩͦ̀ͥȃŕŔłŕɃĳıɓ̜̞͉ͥέͿςΙϋɃĲııůŨİŮōͬഘࠧཋ͂೰̱̹݅শȂଅ௫ພۛ৪͉́Ȃࣞၚͅഘࠧཋેఠ̦ஆह̳̭̦ͥ͂༭̯̞࣬ͦ̀ͥȃ̭ͦͅ‫ڂ‬൚̳ͥۛ৪̦ྕ଻ଅ௫ພː㻙ˑ‫͉́ܢ‬ķı㻙ĸıɓ෇̭̦͛ͣͦͥ͂༭̯̞࣬ͦ̀ͥˑĪȃ̯ͣͅȂਔ౶͈̮̩͂ŦňŇœ̦೩‫̳ئ‬͕ͥ̓ऒ৒๬ఱ͞૤ͼαϋΠ̦௩‫̦̳ͥح‬Ȃഘࠧཋ̭͈͂ͦͣພఠ͈̦‫۾‬Ⴒ̳̥̞ͥ̾̀ࣽͅࢃ಍࿒̱̞̩̭̦̀͂ຈါ̜́ͥȃ৘षͅ൫ଢ଼൵වশ͈‫ޝ‬໐řőષ͈૤‫ڐ‬ఱ͉Ȃŉţ͉͂ඊၛ̱̀ഘࠧཋ̦‫۾‬Ⴒ̳̭ͥ͂͜‫ͅܡ‬༭̯̞࣬ͦ̀ͥ˒Īȃྕ଻ଅ௫ພ͈૷ၷ͈ಎ́Ȃഘ͉௮͈ࠬຈါऺၳ̱͂̀෇ে̯̞̹̦ͦ̀Ȃ̷ͦո‫͈ٸ‬࿨‫̞̀̾͜ͅڬ‬փে̱̀༞ਰ̳ͥຈါ̦̜͈̥̱̞ͥͦ̈́͜ȃଅ଻ຫࠬহၷ͈ࣉ̢༷૤ଅຫࠬછ࢓߲̦̹݃ͩͦાࣣȂˏພఠ̳͓̀ͅచ̱̀൳শͅͺίυȜΙ̳ͥຈါ̦̜ͥȃུࣂ͉́ຫࠬͅచ̳ͥͺίυȜΙܱͬ੆̳ͥȃଅ଻ຫ͈ࠬ͒হၷٚව̳ͬͥஜͅȂུ൚ͅଅ଻ຫ̥͈ࠬ૷౯ͬ‫̪ݢ‬ຈါ̦̜ͥȃ೒ુȂ̷͈૷౯ͅຈါ̈́ࠬಎ͈΀ςΑυε΀Ιϋ౵͈௶೰͉‫ۚܖ‬ພ̤̞֭֭̀͜ͅ‫௶ٸ‬೰̜̭̦́ͥ͂ఉ̞̹͛Ȃତ඾͈ΗͼθρΈ̦୆̲ͥȃ̱̹̦̽̀Ȃ̜ͥ೾ഽଅ‫ܥ‬ෝ̦વ‫̞̯͊ͦ̀ͦٺ‬Ȃଅ଻ຫ̜ࠬ́ͥ͂ࡉၛ̀̀‫ح‬ၷͬ୶࣐̳̭̦̱̱̜ͥ͂͊͊ͥȃඅͅńŌŅĵ‫ܢ‬ո͉ࣛ́࿩˒‫ͅڬ‬ଅ଻ຫࠬͬ෇͛ͥ͂ଔ೰˓ȫ ̯̞ͦ̀ͥȃଅ଻ຫࠬহၷȂ̩͂ͅ૤ଅຫࠬછ࢓߲͈ຫࠬহၷ́ၣփ̳̭͉ͥ͂Ȃల֚ͅഘ͈༞ਰ̜́ͥȃ̱̹̦̽̀Ȃ΀ςΑυε΀Ιϋ͞ŉŊŇ㻙őŉŅ͈ൎဓͬ൳শ࣐̠̥ͅ๛̥͉̥̩͂͜Ȃഘ͈༞ਰ֚ͬ๔ͅࣉ̢ͥȃഘ͉ŉţ͈ΕȜΑ̱̺̫͉̩͂̀́̈́Ȃ૤޼ळ༾ඤ͈́΀ΥσΆȜॲ୆ͅഘ̦ຈଌ˔ȫ̜̥̜́ͥͣ́ͥȃŉŇųņŇۛ৪͈ప֭শ͈ຫࠬ͂ഘࠧཋ͉́Ȃഘࠧཋ͈༷̦ప֭ࢃ͈ထࢃͅ‫˕ ̭̳͂ͥޣג‬ĪȂŉŇųņŇۛ৪͈૤޼޼ळ༾ඤ͉́ഘࠧཋ̦෇̭͛ͣͦͥ͂ĲıĪȂŏŚŉł໦႒ͅਲ̽̀૤ະ஠ਹછ༆ͅႉ઄෸ࠊͬࡉ̧̹͂ȂńœłŔͤ͢͜ńœłŊŅŔȪńŢųŪťŪŰĮœŦůŢŭĮłůŦŮŪŢĮŊųŰů ťŦŧŪŤŪŦůŤź ŴźůťųŰŮŦĻ ńłœłŊŅŔȫ̦ͤ͢ࡐಠ̜́ͤȂഘࠧཋ̦ŉţոષͅਹછഽͬ฽‫̭̞̱͂ͥ̀ד‬ĲĲĪȂထࢃ͒ͼϋΩ·Π͜ഘࠧཋ̦ຫࠬͤ͢͜ਹါ̜̭́ͥ͂Ĳĳȫ̦াऐ̯̞ͦ̀ͥȃ̭͈ાࣣ͈ഘࠧཋ͉Ȃഘ཈გၚɃĳıɓ́୭೰̯̞̭̦ͦ̀ͥ͂ఉ̞ȃ̱̹̦̽̀Ȃຫࠬহၷ͈ΕȜΑ̱͂̀ഘͬൎဓ̳̭ͥ͂͂൳শͅȂવ‫ٺ‬૤޼ͅచ̳ͥ΀ΥσΆȜయ৫٨஝ͬփে̱̹ഘٚව͜ഘ༞ਰ͈փྙ͂̈́ͥȃ४ࣉ́͘ͅࠐ࢛ൎဓ͉́ȂŉŇųņŇۛ৪͈‫׋‬൲ෝ̦٨஝̱̥̹̈́̽༭̦̜࣬ͤĲĴĪȂક‫ۯا‬຾ਆͥ͢ͅഘ͈‫ݟ‬ਓະၻ͜ே೰̯̞̹ͦ̀ͥ͛Ȃે‫୓͉̀̽͢ͅޙ‬ಕൎဓ͜ࣉၪ̳ͥȃ̷͈ࢃȂŉţ౵ͬ४ࣉͅȂņŔłୋसȂŉŊŇ㻙őŉŅͬঀဥ̳̭ͥ͂́Ȃŉţ౵͈ഐୃ‫ͬا‬଎ͥȃഐୃ౵̞͉̾̀ͅ༗ం‫ܢ‬ଅ௫ພۛ৪͈΄ͼΡρͼϋͅ௱ͤȂŉţ౵ĲĲ
㻙ĲĴŨİťōͬ࿒ດ̳͂ͥȃ४ࣉ́͘ͅŉŇųņŇͬచય̱̹͂ρϋΘθ‫ا‬๤‫̞̤̀ͅݪࡄڛ‬ȂņŔłͬঀဥ̱ŉţĲĴర́͘ષઌ̵̯̀͜ĲĲర͈ۛ৪߲͂๤‫̱̀ڛ‬ထࢃͅओ͉෇̞̞̭͛ͣͦ̀̈́͂Ĳĵȫ̥ͣȂ૤ଅຫࠬછ࢓߲͈ۛ৪̤̞̀ͅȂຈ̴̱͜ŉţ౵ͬୃુ౵τασ́͘࿒ດ̳ͥͅຈါ͉̞̈́͂এͩͦͥȃ̤̈́ຫࠬহၷ͈ष͈ഘࠧཋ͈ঐດ͉Ȃࡢ૽എͅŕŔłŕɃĳıɓȂέͿςΙϋĲııůŨİŮōྚྖͅ୭೰̱̞̦̀ͥȂમळ̞͉̾̀ͅଅ଻ຫࠬ΄ͼΡρͼϋͬ४ચ̯̹̞ͦȃɃ̤ͩͤͅɄྕ଻ଅ௫ພૺً࣐೾̤̞̀ͅȂ͈̠̓̈́͢ι΃ΣΒθ́૤ͼαϋΠ̦௩‫͉̞̥̳̀̾ͥͅح‬Ȃྚ̺̳͓̦ٜ̀ྶ̯̹̫͉̞ͦͩ́̈́ȃຫ̺̫͉̩ࠬ́̈́ഘࠧཋ̷͈͜ພఠ͈֚໐ͬ౜̞̽̀ͥ‫خ‬ෝ଻͉๛̞͛̈́ȃຫࠬ͜ഘ͜ႉ઄എͅ༞ୃ‫خ‬ෝ֦̈́ঊ̜́ͤȂ̞ͤࣞ͢փেͬ̽̀͜‫ح‬ၷ̳ͥຈါ̦̜ͥȃɃ၌‫ף‬௖฽Ʉඅ̱̈́ͅɃ४ࣉ໲ࡃɄˍȫŉŢźŢŴũŪ ŕĭ ŋŰŬŪ ŏĭ ŕŢůŢŬŢ Śĭ ŉŢŴŦ ŉĻ Anaemia and early phase cardiovascular eventson haemodialysis. ŏŦűũųŰŭŰŨź ĩńŢųŭŵŰůĪ ĳıĲĶįˎȫŔŪŭŷŦųţŦųŨ ŅŔĭ ŘŦŹŭŦų Ņĭ ŃŭŶŮ Ŏĭ ŕŤũŦţŪůŦų ŋśĭ ŔũŦűŴ Ņĭ ŌŦųŦů ňĭ ŔŤũŸŢųŵŻ ŅĭŃŢųŶŤũ œĭ ŚŢŤũůŪů ŕĭ ŔũŢŬŦť Ŏ Ŧŵ Ţŭ Ļ The effect of correction of anaemia in diabetics
and non-diabetics with severe resistant congestive heart failure and chronic renal failure
by subcutaneous erythropoietin and intravenous iron. ŏŦűũųŰŭ ŅŪŢŭ ŕųŢůŴűŭŢůŵ ĳııĴĭ ĲĹĩĲĪĻ ĲĵĲ㻙ĲĵķįˏȫłůŬŦų ŔŅĭ ńŰŮŪů ńŰŭŦŵ ŋĭ ŇŪŭŪűűŢŵŰŴ ňĭ ŘŪŭŭŦůũŦŪŮŦų œĭ ŅŪŤŬŴŵŦŪů Ōĭ ŅųŦŹŭŦų ŉĭōŶŴŤũŦų ŕŇĭ ŃŢųŵ Ńĭ ŃŢůŢŴŪŢŬ Řĭ ŏŪŦŨŰŸŴŬŢ ŋ Ŧŵ Ţŭ Ļ Ferric carboxymaltose inpatients with heart failure and iron deficiency. ŕũŦ ŏŦŸ ņůŨŭŢůť ūŰŶųůŢŭ Űŧ ŮŦťŪŤŪůŦĳııĺĭ ĴķĲĩĳĶĪĻ ĳĵĴķ㻙ĳĵĵĹį
ːȫőŰůŪŬŰŸŴŬŪ őĭ ŷŢů ŗŦŭťũŶŪŴŦů Ņŋĭ ńŰŮŪůĮńŰŭŦŵ ŋĭ ņųŵŭ ňĭ ŌŰŮŢūťŢ Ŏĭ ŎŢųŦŦŷ ŗĭŎŤŅŰůŢŨũ ŕĭ őŢųŬũŰŮŦůŬŰ łĭ ŕŢŷŢŻŻŪ ōĭ ōŦŷŦŴŲŶŦ ŗ Ŧŵ Ţŭ Ļ Beneficial effects oflong-term intravenous iron therapy with ferric carboxymaltose in patients withsymptomatic heart failure and iron deficiencydagger. ņŶųŰűŦŢů ũŦŢųŵ ūŰŶųůŢŭ ĳıĲĶĭ ĴķĩĲĲĪĻ ķĶĸ㻙ķķĹįˑȫŇŪŴũţŢůŦ Ŕĭ őŰŭŭŢŤŬ Ŕĭ ŇŦŭťŮŢů ŉŊĭ ŋŰŧŧŦ ŎŎĻ Iron indices in chronic kidney disease in
the National Health and Nutritional Examination Survey 1988-2004. ńŭŪů ŋ łŮ ŔŰŤŏŦűũųŰŭ ĳııĺĭ ĵĩĲĪĻ Ķĸ㻙ķĲį˒ȫŉŢźŢŴũŪ ŕĭ ŕŢůŢŬŢ Śĭ ŊŸŢŴŢŬŪ Ŏĭ ŉŢŴŦ ŉĭ ŚŢŮŢŮŰŵŰ ŉĭ ŌŰŮŢŵŴŶ Śĭ łůťŰ œĭŊŬŦťŢ Ŏĭ ŊůŢŨŶŮŢ Ņĭ ŔŢŬŢŨŶŤũŪ ŕ Ŧŵ Ţŭ Ļ Association of Circulatory Iron Deficiency
With an Enlarged Heart in Patients With End-Stage Kidney Disease. ŋ œŦů ŏŶŵų ĳıĲĺĭĳĺĩĲĪĻ Ĵĺ㻙ĵĸį˓ȫŔŰŧŶŦ ŕĭ ŏŢŬŢŨŢŸŢ ŏĭ ŌŢůťŢ ņĭ ŏŢŨŢŴŶ ŉĭ ŎŢŵŴŶŴũŪŵŢ Ōĭ ŏŢůŨŢŬŶ Ŏĭ ŎŢųŶźŢŮŢŔĭ ŘŢťŢ ŕĭ ŕŦųŢťŢ Śĭ ŚŢŮŢŨŢŵŢ Ō Ŧŵ Ţŭ Ļ Prevalence of anemia in patients withchronic kidney disease in Japan: A nationwide, cross-sectional cohort study using datafrom the Japan Chronic Kidney Disease Database (J-CKD-DB). őŭŰŔ ŰůŦ ĳıĳıĭ ĲĶĩĸĪĻŦıĳĴķĲĴĳį˔ȫŷŢů ťŦų ŎŦŦų őĭ ŷŢů ťŦų ŘŢŭ ŉŉĭ ŎŦŭŦůŰŷŴŬź ŗĻ Mitochondrial Function, Skeletal
Muscle Metabolism, and Iron Deficiency in Heart Failure. ńŪųŤŶŭŢŵŪŰů ĳıĲĺĭ ĲĴĺĩĳĲĪĻĳĴĺĺ㻙ĳĵıĳį˕ȫŐŬŰůŬŰ ŅŐĭ ŎŢůťŢŭ łŌĭ ŎŪŴŴŰŶųŪŴ ńňĭ őŰŰŭŦĮŘŪŭŴŰů őłĻ Disordered iron homeostasis
in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity,and survival.

ŋŰŶųůŢŭ Űŧ ŵũŦ łŮŦųŪŤŢů ńŰŭŭŦŨŦ Űŧ ńŢųťŪŰŭŰŨź ĳıĲĲĭ ĶĹĩĲĳĪĻ ĲĳĵĲ㻙ĲĳĶĲįĲıȫŎŦŭŦůŰŷŴŬź ŗĭ őŦŵųŢŬ ŋĭ ŎųŢŤŦŬ ŕĭ ŃŦůŦŴ ŋĭ ŃŰųŭŢŶŨ Ńłĭ ŏŶŴŬŰŷŢ ŉĭ őŭŶũŢŤŦŬ ŕĭŔ ű Ţ ŵ Ŧ ů Ŭ Ţ ŋ ĭ Ō Ű ŷ Ţ ŭ Ť Ū Ŭ Ű ŷ Ţ ŋ ĭ Ņ ų Ţ ũ Ű ŵ Ţ ś Ŧŵ Ţ ŭ Ļ Myocardial iron content andmitochondrial function in human heart failure: a direct tissue analysis. ņŶų ŋ ŉŦŢųŵŇŢŪŭ ĳıĲĸĭ ĲĺĩĵĪĻ Ķĳĳ㻙ĶĴıįĲĲȫłŭůŶŸŢźŴŪų œŊŔĭ ňųŰŵŦ ŃŦŷŦųţŰųŨ ŏĭ ŉŰŦŴ ŎŇĭ ŎŢųŬŰŶŴŪŴĮŎŢŷųŰŨŦůŪŴ ňĭ ňŰŮŦŻŌłĭ ŷŢů ťŦų ŘŢŭ ŉŉĭ ńŭŦŭŢůť ŋňŇĭ ŅŪŤŬŴŵŦŪů Ōĭ ōŢůŨ ńńĭ ŏŨ ōō Ŧŵ Ţŭ Ļ Additional
Burden of Iron Deficiency in Heart Failure Patients beyond the Cardio-Renal-Anaemia
Syndrome: Findings from the BIOSTAT-CHF Study. ņŶų ŋ ŉŦŢųŵ ŇŢŪŭ ĳıĳĲįĲĳȫŌŭŪű Ŋŕĭ ŋŢůŬŰŸŴŬŢ ņłĭ ņůūŶŢůŦŴ ńĭ ŗŰŰųŴ łłĭ ŃŢůŢŴŪŢŬ Řĭ ŃųŶŨŶŦųŢ ŋĭ œŰŻŦůŵųźŵőĭ őŰŭŰůŴŬŪ ōĭ ŷŢů ŗŦŭťũŶŪŴŦů Ņŋĭ őŰůŪŬŰŸŴŬŪ ő Ŧŵ Ţŭ Ļ The additive burden of irondeficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. ņŶųŋ ŉŦŢųŵ ŇŢŪŭ ĳıĲĵĭ ĲķĩķĪĻ ķĶĶ㻙ķķĳįĲĴȫōŦŸŪŴ ňŅĭ ŎŢŭũŰŵųŢ œĭ ŉŦųůŢůťŦŻ łŇĭ ŎŤŏŶŭŵź Ŕņĭ ŔŮŪŵũ łĭ ŇŦŭŬŦų ňŎĭ ŕŢůŨŘŉŘĭ ōŢœŶŦ Ŕŋĭ œŦťŧŪŦŭť ŎŎĭ ŔŦŮŪŨųŢů Ŏŋ Ŧŵ Ţŭ Ļ Effect of Oral Iron Repletion onExercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction andIron Deficiency: The IRONOUT HF Randomized Clinical Trial. ŋłŎł ĳıĲĸĭ ĴĲĸĩĲĺĪĻĲĺĶĹ㻙ĲĺķķįĲĵȫŔŸŦťţŦųŨ Ōĭ ŚŰŶůŨ ŋŃĭ łůŢůť ŊŔĭ ńũŦůŨ Ŕĭ ŅŦŴŢŪ łŔĭ ŅŪŢŻ œĭ ŎŢŨŨŪŰůŪ łőĭŎŤŎŶųųŢź ŋŋĭ ŐĨńŰůůŰų ńĭ őŧŦŧŧŦų Ŏł Ŧŵ Ţŭ Ļ Treatment of anemia with darbepoetin
alfa in systolic heart failure. ŕũŦ ŏŦŸ ņůŨŭŢůť ūŰŶųůŢŭ Űŧ ŮŦťŪŤŪůŦ ĳıĲĴĭ ĴķĹĩĲĴĪĻĲĳĲı㻙ĲĳĲĺį